NEW YORK (GenomeWeb News) – Protagen and the Natural and Medical Sciences Institute at the University of Tubingen announced they will be developing multiplex assays for the diagnosis of autoimmune diseases and cancer.
The deal will leverage Protagen's expertise in the high-throughput expression of human proteins and clinical validation studies, and the institute's research platform.
"For several years our focus has been on development of testing systems using planar and bead-based protein microarrays," Hugo Hämmerle, a professor at NMI, said in a statement. "The competence and capability of our research platform was already validated by a number of projects with international partners from industry and academia. The cooperation with Protagen allows us to collaborate on the commercialization of assays for personalized medicine."
Financial and other terms of the deal were not disclosed.
Protagen is based in Dortmund, Germany and specializes in in vitro diagnostics. The company has two business units, Diagnostics and Protein Services. NIMI also based in Germany is an application-focused research institute that makes research results available to industry.